Brigatinib-话题@MedSci - 梅斯（MedSci）

#Brigatinib#

8篇内容 | 1078人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1943760, encodeId=152a1943e6008, content=<a href='/topic/show?id=f1ed3e3156' target=_blank style='color:#2F92EE;'>#Brigatinib#</a>, objectTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, objectType=article, longId=217316, objectId=e44421e31653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44421e31653, replyNumber=0, likeNumber=84, createdTime=2021-10-28, rootId=0, userName=by2009, userId=2e2c339, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44421e31653, moduleTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e44421e31653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943759, encodeId=7d1b1943e59ed, content=<a href='/topic/show?id=f1ed3e3156' target=_blank style='color:#2F92EE;'>#Brigatinib#</a>, objectTitle=Lung Cancer：布加替尼（brigatinib）治疗既往治疗过的ALK+转移性非小细胞肺癌患者的疗效：真实世界研究, objectType=article, longId=213524, objectId=54582135246b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54582135246b, replyNumber=0, likeNumber=73, createdTime=2022-05-29, rootId=0, userName=by2009, userId=2e2c339, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54582135246b, moduleTitle=Lung Cancer：布加替尼（brigatinib）治疗既往治疗过的ALK+转移性非小细胞肺癌患者的疗效：真实世界研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=54582135246b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943757, encodeId=33801943e57d5, content=<a href='/topic/show?id=f1ed3e3156' target=_blank style='color:#2F92EE;'>#Brigatinib#</a>, objectTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, objectType=article, longId=183563, objectId=716c183563f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=716c183563f0, replyNumber=0, likeNumber=142, createdTime=2020-10-14, rootId=0, userName=by2009, userId=2e2c339, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=716c183563f0, moduleTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=716c183563f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943758, encodeId=92341943e581e, content=<a href='/topic/show?id=f1ed3e3156' target=_blank style='color:#2F92EE;'>#Brigatinib#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=118, createdTime=2020-09-16, rootId=0, userName=by2009, userId=2e2c339, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943756, encodeId=72941943e5690, content=<a href='/topic/show?id=f1ed3e3156' target=_blank style='color:#2F92EE;'>#Brigatinib#</a>, objectTitle=欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌, objectType=article, longId=154589, objectId=7779154589ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7779154589ed, replyNumber=0, likeNumber=111, createdTime=2019-02-24, rootId=0, userName=by2009, userId=2e2c339, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7779154589ed, moduleTitle=欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7779154589ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943755, encodeId=31901943e5595, content=<a href='/topic/show?id=f1ed3e3156' target=_blank style='color:#2F92EE;'>#Brigatinib#</a>, objectTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, objectType=article, longId=149829, objectId=2dc21498290c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dc21498290c, replyNumber=0, likeNumber=98, createdTime=2018-12-07, rootId=0, userName=by2009, userId=2e2c339, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dc21498290c, moduleTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2dc21498290c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943754, encodeId=ee0e1943e5400, content=<a href='/topic/show?id=f1ed3e3156' target=_blank style='color:#2F92EE;'>#Brigatinib#</a>, objectTitle=JCO：不幸中的万幸 —— ALK阳性脑转移NSCLC患者耐药后的新选择：Brigatinib, objectType=article, longId=139302, objectId=203d1393022a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=203d1393022a, replyNumber=0, likeNumber=92, createdTime=2018-06-18, rootId=0, userName=by2009, userId=2e2c339, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=203d1393022a, moduleTitle=JCO：不幸中的万幸 —— ALK阳性脑转移NSCLC患者耐药后的新选择：Brigatinib, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=203d1393022a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943753, encodeId=55451943e535f, content=<a href='/topic/show?id=f1ed3e3156' target=_blank style='color:#2F92EE;'>#Brigatinib#</a>, objectTitle=JCO：Brigatinib二线治疗ALK阳性NSCLC有力量, objectType=article, longId=98708, objectId=105298e082a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=105298e082a, replyNumber=0, likeNumber=96, createdTime=2018-04-28, rootId=0, userName=by2009, userId=2e2c339, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=105298e082a, moduleTitle=JCO：Brigatinib二线治疗ALK阳性NSCLC有力量, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=105298e082a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Brigatinib

2020-05-29

by2009 (审核中...)

前往app查看评论内容

#Brigatinib#

J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果

2021-10-28

by2009 (审核中...)

前往app查看评论内容

#Brigatinib#

Lung Cancer：布加替尼（brigatinib）治疗既往治疗过的ALK+转移性非小细胞肺癌患者的疗效：真实世界研究

2022-05-29

by2009 (审核中...)

前往app查看评论内容

#Brigatinib#

ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势

2020-10-14

by2009 (审核中...)

前往app查看评论内容

#Brigatinib#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2020-09-16

by2009 (审核中...)

前往app查看评论内容

#Brigatinib#

欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌

2019-02-24

by2009 (审核中...)

前往app查看评论内容

#Brigatinib#

2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率

2018-12-07

by2009 (审核中...)

前往app查看评论内容

#Brigatinib#

JCO：不幸中的万幸 —— ALK阳性脑转移NSCLC患者耐药后的新选择：Brigatinib

2018-06-18

by2009 (审核中...)

前往app查看评论内容

#Brigatinib#

JCO：Brigatinib二线治疗ALK阳性NSCLC有力量

2018-04-28

科室
- - 订阅+
  - 更多科室
工具
服务